Transacin (NGX-4010) for Peripheral Neuropathy
People with HIV who have peripheral neuropathy will use either Transacin (capsaicin) patches or very low-dose patches for 30 or 60 minutes a day for 3 months. Participants must be 18 or older and have had pain in both feet for at least 2 months.
People aged 18-65 who have excess abdominal fat will take either TH9507 (an investigational growth hormone releasing factor), or a placebo for 26 weeks. The two groups will then switch for 26 more weeks.
Lauriad for Oral Thrush
People with oral candidiasis will take either Lauriad (miconazole) tablets once a day or clotrimazole troches 5x a day for 2 weeks. Participants must be 18 or older and be on stable HAART for at least 2 months.
Crofelemer for Diarrhea
People 18 and older who have persistent diarrhea will take crofelemer for up to 17 days.
Avandia and Serostim
People with insulin resistance will take Avandia (rosiglitazone), or Serostim (growth hormone), or both for 6 months to see how they affect glucose, insulin levels and body shape.
People aged 18-60 who have taken an NRTI, NNRTI and PI, and have developed resistance or stopped the drugs for other reasons, will take KP-1461 (a new type of NRTI) with no other ARVs for four months.
SPRING: Aptivus in Diverse Populations
People 18 and older (half white and half non-white, half men and half women) who have taken an NRTI, NNRTI and PI (not Aptivus) and who have resistance to at least two PIs, will take a standard dose of Aptivus or receive therapeutic drug monitoring to find the best dose for them.
IMPACT: Reyataz Resistance
People who have developed resistance to Reyataz will come in for one day of blood tests to study the I50L mutation.
TMC 125 Expanded Access
People 18 and older who have limited treatment options and resistance to approved NNRTIs, and who have taken an NRTI, NNRTI and at least two PIs, may qualify for early access to this experimental NNRTI.
Maraviroc Expanded Access
People 16 and older who have taken HAART and who have few treatment options may qualify for early access to this experimental CCR5 attachment inhibitor.
For more information on these trials, contact Dr. Douglas Mendez at 212-924-3934 ext. 126 or Dr. Yuriy Akulov at ext. 124.